Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 10

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  cyclosporin
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1
Content available remote

Worsening of long-term myocardial function after successful pharmacological pretreatment with cyclosporine

100%
Laudi S., Weimann J., Haschke M., Trump S., Schmitz V., Christians U., Kaisers U., Steudel W.
Journal of Physiology and Pharmacology
|
2007
|
tom 58
|
nr 1
Pretreatment with cyclosporine (CsA) decreases infarct size 24h after myocardial ischemia/reperfusion (I/R). The goal of this study was to determine effects of CsA pretreatment on long-term cardiac function after I/R-injury. Rats were randomly assigned to group1: vehicle-only, group2: CsA-5mg/kg/day, and group3: CsA-12.5mg/kg/day given orally for three days prior to I/R-injury (30 min of left anterior descending coronary artery occlusion). Post-I/R survival and cardiac function were evaluated 14 days after I/R-injury by echocardiography and invasive hemodynamic measurements. Rats with I/R-injury showed increased left ventricular pressure (LVEDP) compared to rats without I/R-injury (p<0.005). Although CsA initially decreased infarct size, no differences of LVEDP were seen 14 days after I/R-injury (vehicle: 21.2±8.9 mmHg, CsA-5mg/kg/day: 21.5±0.7 mmHg, CsA-12.5mg/kg/day: 20.5±9.4 mmHg). Ejection fraction and fractional shortening were decreased compared to baseline, but showed no differences between groups. On day 14, a dose-dependent increase in left ventricular end diastolic diameter was seen (p<0.001). CsA pretreatment was associated with a dose-dependent decrease in post-I/R-survival (vehicle: 56%, CsA-5mg/kg/day: 32%, CsA-12.5mg/kg/day: 16%; p=0.017). CsA pretreatment did not improve long-term cardiac function despite decreased infarct size 24h after I/R-injury, but increased post-I/R mortality significantly. Poor cardiac function after CsA pretreatment might be caused by left ventricular dilation.
2
Content available remote

The influence of the tumor necrosis factor-alpha-308G>A polymorphism on the efficacy of immunosuppressive therapy in patients after kidney transplantation

72%
Kotowski M., Bogacz A., Bartkowiak-Wieczorek J., Sienko J., Procyk D., Dziewanowski K., Ostrowski M., Czerny B., Grzeskowiak E., Machalinski B.
Journal of Physiology and Pharmacology
|
2016
|
tom 67
|
nr 6
3
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

The evaluation of canine atopic dermatitis extent and severity index (CADESI) test in dogs with atopic dermatitis (AD) treated with cyclosporine or prednisone

72%
Taszkun I.
Polish Journal of Veterinary Sciences
|
2010
|
tom 13
|
nr 4
The purpose of this study was to assess the clinical state of dogs with atopic dermatitis (AD) by use of CADESI test in own modification during the first visit in the Dermatology Consult Room as well as during the treatment. The study was performed in two groups (I-E and II-C) of 20 dogs in each group. In dogs which were qualified to the I-E group, as antiallergic, anti-inflammatory and antipruritic treatment, prednisone (oral preparation Encorton – Polfa Pabianice) at dose 0.5 mg/kg b.w./day was administered, while in dogs qualified to the II-C group – cyclosporine (oral preparation Sandimmun Neoral – Novartis Pharma) at a dose of 5 mg/kg b.w./day; the treatment was continued for 6 weeks in both groups. During the study, skin lesions were assessed in 15 specified body areas using 4 parameters and 5-point scale. In group I-E and II-C the amount of received points in CADESI test was decreased by 82.26% and by 83% respectively, after the treatment. Statistical analyses of the results obtained revealed no statistically significant (P=0.05) differences between means of I-E and II-C groups in consecutive examinations, which indicates comparable clinical efficacy of both drugs. Statistically significant differences (P=0.05) of the parameters assessed were found after secondary dermatoses treatment, and after every two weeks of antipruritic and anti-inflammatory treatment.
4

The complexities of CD28 and CTLA-4 signalling: PI3K and beyond

72%
Ward S. G.
Archivum Immunologiae et Therapiae Experimentalis
|
1999
|
tom 47
|
nr 2
5

Cladribine [2-chloro-2'-deoxyadenosine]: new perspectives in clinical immunosuppression

72%
Gorski A., Grieb P.
Archivum Immunologiae et Therapiae Experimentalis
|
1994
|
tom 42
|
nr 1
6

Assessment of pruritus using pruritus score test in dogs with atopic dermatitis treated with cyclosporine or prednisone

58%
Taszkun I.
Bulletin of the Veterinary Institute in Puławy
|
2010
|
tom 54
|
nr 4
The purpose of this study was to evaluate the suitability of pruritus score test in pruritus diagnosis in dogs. The test was used to assess the frequency and severity of pruritus in dogs between 1 and 3 years of age, suffering from atopic dermatitis. Skin pruritus was assessed: during the first visit (examination 0), after elimination of secondary dermatosis (examination 1), 2 weeks after the treatment with prednisone - group I-E or cyclosporine - group II-C (examination 2) as well as 6 weeks after treatment (examination 3). In examination 0, the skin pruritus in all dogs was scored at 26.75%. Reduction of pruritus was observed during the treatment in examination 3 in dogs of group I-E (by 80.46%) and in dogs of group II-C (by 86.12%) in comparison with examination 0. Localisation of pruritus in particular body parts was also examined, resulting in observation that in examination 0 it was mostly found in interdigital space of front paws, facial part of the muzzle, chin, ears but not always with the same intensity in symmetrically placed body parts. Mean values of the measurement were statistically significant (P≤0.005) after 2, 4, and 6 weeks of the treatment in I-E and II-C groups. No statistically significant differences were observed between I-E and II-C groups in consecutive measurements.
7

Antibodies in the treatment of aplastic anemia

58%
Gomez-Almaguer D., Jaime-Perez J. C., Ruiz-Arguelles G. J.
Archivum Immunologiae et Therapiae Experimentalis
|
2012
|
tom 60
|
nr 2
8

Use of specific anti-HLA antibodies in clinical nephrology

51%
Buglova S. E., Levin V. I., Pilotovich V. S., Kozlov G. T., Drapezo L. N.
Archivum Immunologiae et Therapiae Experimentalis
|
1995
|
tom 43
|
nr 2
9

Sirolimus in transplantation

51%
Stepkowski S. M., Tian L., Wang M. E., Qu X., Napoli K., Kahan B. D.
Archivum Immunologiae et Therapiae Experimentalis
|
1997
|
tom 45
|
nr 5-6
10

Atopowe zapalenie skóry u psów - najnowsze wiadomości na temat rozpoznawania i leczenia

37%
Banovic F.
Weterynaria po Dyplomie
|
2019
|
tom 20
|
nr 3
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.